fbpx

Check out the latest episodes of our Life Science and Food Industry Podcasts. Available everywhere!

X

Eli Lilly’s Olumiant FDA Approved for Alopecia + Alnylam’s RNAi Drug Amvuttra Approved for Rare Protein Disorder – Xtalks Life Science Podcast Ep. 66

Eli Lilly’s Olumiant FDA Approved for Alopecia + Alnylam’s RNAi Drug Amvuttra Approved for Rare Protein Disorder – Xtalks Life Science Podcast Ep. 66

Photo: Business Wire

In this episode, Ayesha and the team talked about the FDA approval of Eli Lilly’s JAK inhibitor Olumiant for the treatment of alopecia areata, also commonly just known as alopecia. The drug has become the first approved systemic treatment for the autoimmune disorder that causes patchy hair loss. Hear about how alopecia has received mainstream recognition because of a recent infamous Hollywood incident and the importance of raising awareness about rare diseases like alopecia.

Ayesha also discussed the FDA approval of Alnylam’s RNAi therapeutic Amvuttra for the treatment of polyneuropathy associated with a rare protein disorder called hereditary transthyretin-mediated (ATTR) amyloidosis. Hear about how the drug is also being evaluated for another type of (ATTR cardiomyopathy) and the other big players in the ATTR space including Pfizer and AstraZeneca.

Listen on Apple Podcasts

Read the full articles here:

Eli Lilly’s Olumiant Wins FDA Approval as First Systemic Treatment for Alopecia Areata

Amvuttra RNAi Therapeutic Wins FDA Approval for Rare Genetic Protein Disorder

The weekly podcast is available for streaming every Wednesday on SpotifyApple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.